Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Open Access
- 28 February 2007
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 153 (2) , 182-188
- https://doi.org/10.1016/j.ahj.2006.10.034
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Effect of letrozole on the lipid profile in postmenopausal women with breast cancerEuropean Journal Of Cancer, 2001
- Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancerBreast Cancer Research and Treatment, 1996
- New endocrine therapies for breast cancerEuropean Journal Of Cancer, 1996
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levelsBreast Cancer Research and Treatment, 1988
- Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham populationPublished by Elsevier ,1986